Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

209.46
-2.2750-1.07%
Post-market: 209.500.0400+0.02%19:50 EDT
Volume:2.12M
Turnover:444.42M
Market Cap:44.89B
PE:-23.48
High:212.74
Open:212.06
Low:206.75
Close:211.74
52wk High:220.34
52wk Low:35.62
Shares:214.34M
Float Shares:184.00M
Volume Ratio:1.37
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:17.23
PE(LYR):-35.20

Loading ...

Revolution Medicines Is Maintained at Buy by Needham

Dow Jones
·
May 07

Ami Fadia Reiterates Buy on Revolution Medicines, Slightly Lowers Price Target to $183 Amid Higher Non‑Cash Expenses and Expanded RASolute 301 Trial

TIPRANKS
·
May 07

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Sera Prognostics (SERA)

TIPRANKS
·
May 07

Revolution Medicines Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects

Reuters
·
May 07

Earnings Flash (RVMD) Revolution Medicines Posts Q1 Per Share Loss $-2.29, vs. FactSet Est Loss of $-1.85

MT Newswires Live
·
May 07

Revolution Medicines Q1 net loss widens to $453.8 million

Reuters
·
May 07

Revolution Medicines Q1 EPS $(2.29) Misses $(1.82) Estimate

Benzinga Earnings
·
May 07

BRIEF-Revolution Medicines Q1 EPS USD -2.29

Reuters
·
May 07

Revolution Medicines Q1 Operating Expenses USD 445.222 Million

THOMSON REUTERS
·
May 07

Revolution Medicines Inc - Updates FY2026 Gaap Operating Expenses Guidance to $1.7-$1.8 Bln

THOMSON REUTERS
·
May 07

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

GlobeNewswire
·
May 07

BRIEF-FDA Issues “Safe To Proceed” Letter To Initiate EAP For Revolution Medicines' Daraxonrasib

Reuters
·
May 02

FDA permits expanded access for Revolution pancreatic cancer drug

TIPRANKS
·
May 02

Revolution Medicines: FDA Issued “Safe to Proceed” Letter to Initiate Expanded Access Treatment Protocol for Daraxonrasib for Pancreatic Cancer

THOMSON REUTERS
·
May 01

F.d.a. Grants Early Access to Promising Drug for Pancreatic Cancer - NYT

THOMSON REUTERS
·
May 01

FDA clears Revolution Medicines expanded access protocol for daraxonrasib in metastatic pancreatic cancer

Reuters
·
May 01

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini sells 3,120 shares for $416,020.49

Reuters
·
Apr 30

Revolution Medicines to report first-quarter results after market close

Reuters
·
Apr 30

Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

GlobeNewswire
·
Apr 30